Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
Eton Pharmaceuticals (ETON) has scheduled a virtual Investor Day and Q4 2024 earnings release for March 18, 2025, at 10:00 a.m. ET. The event will provide investors with a comprehensive overview of the company's rare disease portfolio and financial outlook following a transformative six-month period.
The presentation will focus on the market potential and commercial strategies for recently acquired products Increlex® and Galzin®, along with updates on their adrenal insufficiency franchise including Alkindi Sprinkle® and ET-400. Management will also discuss developments in their rare disease pipeline.
Key speakers include CEO Sean Brynjelsen, CFO James Gruber, CBO David Krempa, and CCO Ipek Erdogan-Trinkaus. A Q&A session will follow the presentation, with the webcast recording available for 30 days after the event.
Eton Pharmaceuticals (ETON) ha programmato un Investor Day virtuale e la pubblicazione dei risultati del quarto trimestre 2024 per il 18 marzo 2025, alle 10:00 ET. L'evento fornirà agli investitori una panoramica completa del portafoglio dell'azienda sulle malattie rare e delle prospettive finanziarie dopo un periodo trasformativo di sei mesi.
La presentazione si concentrerà sul potenziale di mercato e sulle strategie commerciali per i prodotti recentemente acquisiti Increlex® e Galzin®, insieme agli aggiornamenti sulla loro linea di prodotti per l'insufficienza surrenalica, inclusi Alkindi Sprinkle® e ET-400. La direzione discuterà anche degli sviluppi nel loro pipeline di malattie rare.
I relatori principali includono il CEO Sean Brynjelsen, il CFO James Gruber, il CBO David Krempa e il CCO Ipek Erdogan-Trinkaus. Seguirà una sessione di domande e risposte dopo la presentazione, con la registrazione del webcast disponibile per 30 giorni dopo l'evento.
Eton Pharmaceuticals (ETON) ha programado un Día del Inversor virtual y la publicación de resultados del cuarto trimestre de 2024 para el 18 de marzo de 2025, a las 10:00 a.m. ET. El evento proporcionará a los inversores una visión completa del portafolio de la empresa sobre enfermedades raras y las perspectivas financieras tras un periodo transformador de seis meses.
La presentación se centrará en el potencial de mercado y las estrategias comerciales para los productos adquiridos recientemente Increlex® y Galzin®, junto con actualizaciones sobre su franquicia de insuficiencia adrenal, incluidos Alkindi Sprinkle® y ET-400. La dirección también discutirá los desarrollos en su pipeline de enfermedades raras.
Los oradores principales incluirán al CEO Sean Brynjelsen, al CFO James Gruber, al CBO David Krempa y a la CCO Ipek Erdogan-Trinkaus. Después de la presentación, habrá una sesión de preguntas y respuestas, con la grabación del webcast disponible durante 30 días después del evento.
Eton Pharmaceuticals (ETON)는 2025년 3월 18일 오전 10시(동부 표준시)에 가상 투자자 데이 및 2024년 4분기 실적 발표를 예정하고 있습니다. 이 이벤트는 투자자들에게 회사의 희귀 질환 포트폴리오와 변화하는 6개월 기간 이후의 재무 전망에 대한 포괄적인 개요를 제공합니다.
발표는 최근 인수한 제품 Increlex®와 Galzin®의 시장 잠재력 및 상업 전략에 초점을 맞추고, Alkindi Sprinkle®와 ET-400을 포함한 그들의 부신 insufficiency 프랜차이즈에 대한 업데이트를 제공합니다. 경영진은 또한 희귀 질환 파이프라인의 개발 상황에 대해서도 논의할 것입니다.
주요 연사는 CEO Sean Brynjelsen, CFO James Gruber, CBO David Krempa, CCO Ipek Erdogan-Trinkaus입니다. 발표 후 질의응답 세션이 진행되며, 이벤트 후 30일 동안 웹캐스트 녹화가 제공됩니다.
Eton Pharmaceuticals (ETON) a programmé une journée virtuelle pour les investisseurs et la publication des résultats du quatrième trimestre 2024 pour le 18 mars 2025 à 10h00 ET. L'événement fournira aux investisseurs un aperçu complet du portefeuille de l'entreprise en matière de maladies rares et des perspectives financières après une période de transformation de six mois.
La présentation se concentrera sur le potentiel du marché et les stratégies commerciales pour les produits récemment acquis Increlex® et Galzin®, ainsi que sur les mises à jour de leur franchise d'insuffisance surrénalienne, y compris Alkindi Sprinkle® et ET-400. La direction discutera également des développements dans leur pipeline de maladies rares.
Les intervenants clés incluent le PDG Sean Brynjelsen, le directeur financier James Gruber, le directeur commercial David Krempa et la directrice de la communication Ipek Erdogan-Trinkaus. Une session de questions-réponses suivra la présentation, et l'enregistrement du webinaire sera disponible pendant 30 jours après l'événement.
Eton Pharmaceuticals (ETON) hat einen virtuellen Investorentag und die Veröffentlichung der Ergebnisse für das vierte Quartal 2024 für den 18. März 2025 um 10:00 Uhr ET angesetzt. Die Veranstaltung wird den Investoren einen umfassenden Überblick über das Portfolio des Unternehmens im Bereich seltener Krankheiten und die finanziellen Aussichten nach einem transformierenden Zeitraum von sechs Monaten bieten.
Die Präsentation wird sich auf das Marktpotenzial und die kommerziellen Strategien für die kürzlich erworbenen Produkte Increlex® und Galzin® konzentrieren, sowie auf Updates zu ihrer Franchise für Nebenniereninsuffizienz, einschließlich Alkindi Sprinkle® und ET-400. Das Management wird auch Entwicklungen in ihrer Pipeline seltener Krankheiten besprechen.
Zu den Hauptrednern gehören CEO Sean Brynjelsen, CFO James Gruber, CBO David Krempa und CCO Ipek Erdogan-Trinkaus. Im Anschluss an die Präsentation wird es eine Fragerunde geben, und die Aufzeichnung des Webcasts wird 30 Tage nach der Veranstaltung verfügbar sein.
- Recently completed acquisitions of Increlex® and Galzin® products
- Expanding rare disease portfolio with multiple products
- Management describes past 6 months as transformational
- None.
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT).
In addition to discussing fourth quarter 2024 financial results, the Investor Day event will offer investors an in-depth look at Eton’s rare disease portfolio and financial outlook after a transformational six months. The company will share its view of the long-term market opportunity and commercial strategy for the recently acquired Increlex® and Galzin® products, as well as provide an update on its adrenal insufficiency franchise, Alkindi Sprinkle® and ET-400, and the associated market landscape. In addition, the company will highlight recent developments within its pipeline of attractive rare disease product candidates. Featured speakers include Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, David Krempa, Chief Business Officer, and Ipek Erdogan-Trinkaus, Chief Commercial Officer. Audience members will have the opportunity to ask questions following the prepared remarks.
To participate, please click here to register. An archived webcast will be available on the Investors section of Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
When is Eton Pharmaceuticals (ETON) hosting its Q4 2024 earnings call and Investor Day?
What products will be discussed during ETON's March 2025 Investor Day?
Who are the key executives presenting at ETON's 2025 Investor Day?
How long will ETON's Investor Day webcast recording be available?
